Showing results (161-170 of 305) with videos related to

Sort By:
Pageof 31
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 24, 2010
Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myelomaMarco Ladetto, Gloria Pagliano, Simone Ferrero, et al.
Haematologica|April 1, 2021
European Myeloma Network perspective on CAR T-Cell therapies for multiple myelomaBenedetto Bruno, Ralph Wäsch, Monika Engelhardt, et al.
Blood|May 24, 2014
Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 studySara Bringhen, Maria Teresa Petrucci, Alessandra Larocca, et al.
Haematologica|February 29, 2020
Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studiesRoberto Mina, Francesca Bonello, Maria Teresa Petrucci, et al.
Cancer|December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisManuela Gambella, Paola Omedé, Stefano Spada, et al.
The Journal of Molecular Diagnostics : JMD|August 31, 2015
Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCRDaniela Drandi, Lenka Kubiczkova-Besse, Simone Ferrero, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
Leukemia & Lymphoma|June 1, 2010
Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approachesMonika Engelhardt, Martina Kleber, Josefina Udi, et al.
Blood|August 20, 2013
Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label studyAlessandra Larocca, Vittorio Montefusco, Sara Bringhen, et al.
Clinical Lymphoma, Myeloma & Leukemia|July 3, 2026
Clinical and Biological Implications of TP53 Abnormalities in Relapsed/Refractory Multiple Myeloma: The DEDALO StudyVittorio Montefusco, Anna Maria Cafro, Gloria Margiotta-Casaluci, et al.
Pageof 31